Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Found 1 result for 31721897
Filters applied. Clear filters
Observational Study
. 2019 Nov 7:18:eAO5029.
doi: 10.31744/einstein_journal/2020AO5029. eCollection 2020.

Use of misoprostol in the treatment of postpartum hemorrhage: a pharmacoepidemiological approach

[Article in English, Portuguese]
Daeska Marcella Koch  1 , Yanna Dantas Rattmann  1
Affiliations
Observational Study

Use of misoprostol in the treatment of postpartum hemorrhage: a pharmacoepidemiological approach

[Article in English, Portuguese]
Daeska Marcella Koch et al. Einstein (Sao Paulo). .

Abstract
in English, Portuguese

Objective: To characterize the use of the drug misoprostol for treatment of postpartum hemorrhage in pregnant women.

Methods: A descriptive observational study was carried out with secondary data from pregnant women who used misoprostol to treat postpartum hemorrhage in a reference public maternity, from July 2015 to June 2017. Clinical and sociodemographic profiles of pregnant women, how misoprostol was used and success rate in controling postpartum hemorrhage were characterized.

Results: A total of 717 prescriptions of misoprostol were identified. Of these, 10% were for treatment of postpartum hemorrhage. The majority of pregnant women were young adults, married, with complete high school education, white, residing in urban areas, multiparous (68.1%) and 25% had previous cesarean sections. The mean gestational age was 39 weeks and 51.4% had a cesarean section. There was prophylactic use of oxytocin in 47.2% of women. Treatment of postpartum hemorrhage was successful in 84.7% of women. Of these, 79.2% also used oxytocin and 54.2% methylergonovine. Only 13.5% of pregnant women had less than five prenatal visits, and the main cause of postpartum hemorrhage was uterine atony. There were 13 complications after hemorrhage, 15.3% required blood transfusion and there was one case of maternal death.

Conclusion: Misoprostol showed to be effective and safe for treating postpartum hemorrhage.

Objetivo: Caracterizar o uso do medicamento misoprostol para o tratamento da hemorragia pós-parto em gestantes.

Métodos: Estudo observacional descritivo realizado por meio de dados secundários de gestantes que fizeram uso do misoprostol para tratamento da hemorragia pós-parto em maternidade pública de referência, no período de julho de 2015 a junho de 2017. Caracterizaram-se os perfis clínico e sociodemográfico das gestantes, o padrão de utilização do misoprostol e sua taxa de sucesso no controle da hemorragia pós-parto.

Resultados: Foram identificadas 717 prescrições do misoprostol. Destas, 10% foram para tratamento da hemorragia pós-parto. Predominaram gestantes adultas jovens, casadas, com Ensino Médio completo, raça branca, da região urbana, multíparas (68,1%) e 25% apresentavam cesáreas prévias. A idade gestacional média foi 39 semanas e 51,4% das gestantes tiveram parto cesárea. Houve uso profilático de ocitocina em 47,2% das mulheres. O tratamento da hemorragia pós-parto eve sucesso em 84,7% das gestantes que usaram misoprostol. Destas, 79,2% também usaram ocitocina e 54,2% metilergometrina. Apenas 13,5% das gestantes tiveram menos de cinco consultas de pré-natal, e a principal causa da hemorragia pós-parto foi atonia uterina. Foram registrados 13 casos de complicações após a hemorragia, 15,3% necessitaram de hemotransfusão e houve um caso de óbito materno.

Conclusão: O misoprostol demonstrou ser efetivo e seguro para o tratamento da hemorragia pós-parto.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: none.

Similar articles

See all similar articles

Cited by

References

    1. 1. Organização Mundial da Saúde (OMS). Recomendações da OMS para a prevenção e tratamento da hemorragia pós-parto [Internet]. Brasília (DF): OMS; 2014 [citado 2019 Fev 4]. Disponível em: https://apps.who.int/iris/bitstream/handle/10665/75411/9789248548505_por...
    2. Organização Mundial da Saúde (OMS) Recomendações da OMS para a prevenção e tratamento da hemorragia pós-parto. Brasília (DF): OMS; 2014. [citado 2019 Fev 4]. Internet]. https://apps.who.int/iris/bitstream/handle/10665/75411/9789248548505_por....
    1. 2. Souza ML, Laurenti R, Knobel R, Monticelli M, Brüggemann OM, Drake E. Mortalidade materna por hemorragia no Brasil. Rev Lat Am Enfermagem. 2013;21(3):1-8. - PubMed
    2. Souza ML, Laurenti R, Knobel R, Monticelli M, Brüggemann OM, Drake E. Mortalidade materna por hemorragia no Brasil. Rev Lat Am Enfermagem. 2013;21(3):1–8. - PubMed
    1. 3. Carroli G, Cuesta C, Abalos E, Gulmezoglu AM. Epidemiology of postpartum haemorrhage: a systematic review. Best Pract Res Clin Obstet Gynaecol. 2008;22(6):999-1012. Review. - PubMed
    2. Carroli G, Cuesta C, Abalos E, Gulmezoglu AM. Epidemiology of postpartum haemorrhage: a systematic review. Best Pract Res Clin Obstet Gynaecol. 2008;22(6):999–1012. Review. - PubMed
    1. 4. Frass KA. Postpartum hemorrhage is related to the hemoglobin levels at labor: observational study. Alexandria J Med. 2015;51(4):333-7.
    2. Frass KA. Postpartum hemorrhage is related to the hemoglobin levels at labor: observational study. Alexandria J Med. 2015;51(4):333–337.
    1. 5. Mousa HA, Alfirevic Z. Treatment for primary postpartum haemorrhage.Cochrane Database Syst Rev. 2007;13(1):CD003249. Review. - PubMed
    2. Mousa HA, Alfirevic Z. Treatment for primary postpartum haemorrhage. Cochrane Database Syst Rev. 2007;13(1):CD003249. Review. - PubMed

Publication types